Compare ESP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | SLS |
|---|---|---|
| Founded | 1928 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 208.0M |
| IPO Year | N/A | N/A |
| Metric | ESP | SLS |
|---|---|---|
| Price | $44.34 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 15.8K | ★ 4.5M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $13.74 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $24.85 | $0.77 |
| 52 Week High | $55.00 | $2.48 |
| Indicator | ESP | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 72.49 |
| Support Level | $41.30 | $1.92 |
| Resistance Level | $45.00 | $2.12 |
| Average True Range (ATR) | 1.69 | 0.16 |
| MACD | 0.41 | 0.07 |
| Stochastic Oscillator | 70.20 | 92.77 |
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.